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Subtulene A, a new cyclic lipopeptide, was isolated from the culture broth of Bacillus subtilis SSE4.
This antibiotic compound contained the seven common a-amino acids, L-Asn-1, D-Tyr-2, D-Asn-3, L-
Gln-4, L-Pro-5, D-Asn-6, L-Ser-7 and the unique b-amino acid-8 present in the iturin family. 1D and 2D
NMR, as well as MS analyses, identiﬁed the b-amino acid as 3-amino-13-methyltetradec-8-enoic
acid, an Iso C15 long chain b-amino acid. B. subtilis SSE4 was also found to produce iturin A. B. sub-
tilis SSE4 culture ﬁltrate exhibited both antifungal and antibacterial activities.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The iturins, produced by several strains of Bacillus subtilis, are
cyclic lipopeptide antibiotics [1,2]. Iturins A–E [3–5], bacillomycins
D, F, L and Lc [6–10], and mycosubtilin [11] have been previously
described as the main variants of the iturin family. They are cyclic
lipopeptides containing a heptapeptide of a-amino acids that is cy-
clized with a C13 to C17 b-amino fatty acid (Table 1, entries 1–8).
The a-amino acids of the heptapeptide are arranged in the
constant chiral sequence, LDDLLDL and the stereochemistry of
the b-amino fatty acid side chain has been determined to be in
the R-conﬁguration at the b-carbon [1]. The length of the fatty acid
side chain (R) of iturinic acid varies from 10 to 14 carbons (C13 to
C17 total carbons) in the n-, iso-, or anteiso-conﬁgurations. These
can give rise to eight distinct iturin isomers (A1–A8) based onchemical Societies. Published by E
, dimethyl sulfoxide
Biotechnology, Chulabhorn
ngkok 10210, Thailand. Fax:chain length. Of these, the n-C14 isomer (iturin A2) is the predom-
inant isomer in iturin A [12].
Previous biological activity studies have shown iturins to be
effective antibiotics against bacteria and fungi [13]. The ﬁrst three
amino acids, L-Asx (x = p or n), D-Tyr, and D-Asn, are conserved in
this family and are known to play an important role in antibiotic
action. For example, the replacement of L-Asn-1 of iturin A by
L-Asp-1 in iturin C abolishes antibiotic action [10]. Also, the
methylation of the phenoxyl group of the D-Tyr-2 residue of iturin
A dramatically decreases the activity [14,15]. Mycosubtilin differs
from iturinA only by the sequence inversion of the two amino acid
residues, D-Ser-6 and L-Asn-7. However, they have different confor-
mation and mycosubtilin is more active than iturinA [2]. The side
chain length of iturinic acid is also critically important. The syn-
thetic cyclopeptide (SCP) which contains b-alanine instead of ituri-
nic acid to give only the iturin peptide core, loses antibiotic activity
(Table 1, entry 7) [10].
Herein, we report the isolation of B. subtilis SSE4 that
extracellularly produces two antibiotic compounds: iturin A
and the novel lipopeptide, subtulene A (Table 1, entry 9). The
structure of the b-amino acid of subtulene A was determinedlsevier B.V. All rights reserved.
Table 1
Amino acid composition of the iturin family and compositional differences of the b-
amino acid.a
A7 A4
A3
A2
A1
HN
A6 A5
O
R 8
n-C13: R = CH2CH3
n-C14: R = CH2CH2CH3
anteiso-C15: R = CH(CH3)CH2CH3
iso-C15: R = CH2CH(CH3)2
n-C15: R = CH2CH2CH2CH3
iso-C16: R = CH2CH2CH(CH3)2
n-C16: R = CH2CH2CH2CH2CH3
anteiso-C17: R = CH2CH2CH(CH3)CH2CH3
Entry Antibiotic Amino acid sequences
L-A1-D-A2-D-A3-L-A4-L-A5-D-A6-L-A7
1 Iturin A Asn-Tyr-Asn-Gln-Pro-Asn-Ser
2 Iturin C Asp-Tyr-Asn-Gln-Pro-Asn-Ser
3 Bacillomycin D Asn-Tyr-Asn-Pro-Glu-Ser-Thr
4 Bacillomycin F Asn-Tyr-Asn-Gln-Pro-Asn-Thr
5 Bacillomycin L Asp-Tyr-Asn-Ser-Glu-Ser-Thr
6 Bacillomycin Lc Asn-Tyr-Asn-Ser-Glu-Ser-Thr
7 SCPb Asp-Tyr-Asn-Ser-Glu-Ser-Thr
8 Mycosubtilin Asn-Tyr-Asn-Gln-Pro-Ser-Asn
9 Subtulene Ac Asn-Tyr-Asn-Gln-Pro-Asn-Ser
a Normal b-amino acid side chain (C13 to C17).
b SCP is the synthetic cyclopeptide (b-amino acid = Ala).
c b-Amino acid side chain is 3-amino 13-methyltetradec-8-enoic acid
(R = (CH2)3CH@CH(CH2)3CH(CH3)2).
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novel side chain structure for this class of lipopeptide. The bio-
logical activities of subtulene A are also reported.
2. Materials and methods
2.1. Isolation of B. subtilis SSE4
Samples from shrimp shell waste were serially diluted and
spread on tryptic soy agar (TSA) supplemented with 100 lg/ml
ketoconazole to inhibit fungal growth. All plates were incubated
at 28 C in the dark for 24 h.
2.2. Antagonistic activity screening using the dual culture technique
The phytopathogenic fungi, Colletotrichum gloeosporioides
DOAC1690 and Sclerotium rolfsii DOAC 1521 were maintained on
potato dextrose agar (PDA) plates at 28 C in the dark for 4 days.
Mycelium tip of 4-day-old culture was used as the inoculum for
this experiment. A bacterial isolate was aerobically cultivated at
28 C with shaking at 150 rpm for 18 h. Twenty microliters of bac-
terial suspension (OD600 0.1) was placed onto one side of a PDA
plate. The plates were incubated at 28 C for 2 days. A 6-mm diam-
eter plug, taken from the margin of a 4-day-old PDA plate with
conﬂuent growth of a fungal pathogen, was placed onto the center
of the plate previously inoculated with the bacterial suspension.
The plate was then incubated at 28 C and the extent of fungal
growth inhibition was examined after 5–7 days of incubation.
The level of inhibition was calculated as previously reported [16].
2.3. Identiﬁcation of bacteria by 16S ribosomal RNA gene sequencing
Strain SSE4 was gram stained and found to be a Gram positive
rod. In order to precisely identify this bacterium, the sequence of
part of the 16S ribosomal RNA gene was determined. PCR ampliﬁ-
cation of the 16S rRNA gene with the universal primers of forward
F (50-AGAGTTTGATCCTGGCTCAG-30) and reverse R (50-ACCAGGG-
TATCTAATCCTGT-30) was carried out and the resulting 755 bp
product was sequenced [17]. The sequences were compared to
those found in the Genbank database. PCR ampliﬁcation conditions
were as follows: preheated at 94 C for 5 min then 35 cycles of94 C for 45 s, annealed at 55 C for 45 s and extend at 72 C for
45 s.
2.4. Preparation of cell-free culture ﬁltrate
Bacterial cells were cultivated in TSB and incubated with con-
tinuous shaking at 28 C. The supernatant was collected at 4 h
(exponential phase) and 48 h (stationary phase) by centrifugation
at 8000 rpm for 20 min at 4 C. The supernatant was rendered
cell-free by ﬁltration through a sterile membrane with a 0.45 lm
pore size and stored at 4 C until further use in the antifungal
assay.
2.5. Radial growth inhibition assay
Culture ﬁltrate was added to warmmolten PDA (at 45 C) to a ﬁ-
nal concentration of 20% (v/v). A 6 mm-diametermycelial plug from
a 3-day-old plate culture of either Colletotrichum gloeosporioides or
Sclerotium rolfsiiwas placed in the center of the PDA plate followed
by incubation at 28 C in the dark. Mycelial growth was measured
daily until the fungal mycelia on the control plate reached the edge
of the plate. Fungal growth inhibitionwas expressed as the percent-
age of inhibition of radial growth relative to the control.
2.6. Protection against anthracnose disease caused by C.
gloeosporioides
Bioassays for suppression of fungal diseases caused by C. gloeo-
sporioides were performed using 1-year-old Dendrobium orchid
plants. The experiment used a Completely Randomized Design
(CRD) which was divided into ﬁve treatments with ﬁve replica-
tions. Both culture ﬁltrate and a fungal pathogen were not applied
in T1 as negative control. Orchid leaves were inoculated with C.
gloeosporioides as positive control (T2). The surface of orchid leaf
was sprayed with 200 ll of 1 mg/ml of mancozeb as chemical anti-
fungal agent for T3. Two hundred microliters of exponential (T4) or
stationary (T5) culture ﬁltrates were applied on the abaxial surface
of the leaf. The abaxial surface of the orchid leaf was then scratched
with a sterile needle. A piece of a 6-mm plug of C. gloeosporioides
was then placed on the surface for all treatments, except T1. The
inoculated orchid plants were covered with polyethylene bags for
24 h. The size of visible anthracnose disease lesions on the orchid
leaves was measured daily for 5 days.
2.7. Fractionation and puriﬁcation of the bioactive compounds
The supernatant from 1 l of stationary phase B. subtilis SSE4 cul-
ture was extracted once with hexane, (ratio 1:1). After extraction
with hexane, the supernatant was extracted twice with ethyl ace-
tate, (ratio 1:1). The ethyl acetate fractions were combined and
concentrated by evaporation at temperature <40 C to give a dried
powder residue. The dried residue was then dissolved in 4 ml
methanol (100%) and subjected to preparative HPLC (Waters Delta
600, Massachusetts, USA). The preparative HPLC was performed
using a Sunﬁre Prep™ C18, 5 lm, OBD 19  150 mm column
(Waters, Massachusetts, USA). The mobile phase was water (A)
and methanol (B) at a ﬂow rate of 20 ml/min. The detection wave-
length was set at 230 nm. The gradient system started from 0 min
(5% B) to 5 min (30% B), 10 min (55% B), 13 min (70% B), 17 min
(70% B), 22 min (90% B), 24 min (5% B) and maintained at this ratio
until 27 min. The temperature of the column was 25 C.
2.8. Microbial sensitivity assays
In order to test the susceptibility of various microorganisms,
disk inhibition assay was performed as previously described [18].
Fig. 1. The radial growth inhibition of C. gloeosporioides and S. rolfsii on PDA plates
containing stationary phase culture ﬁltrate of B. subtilis SSE4 in various concentra-
tions. (A) Control, (B) 10%, (C) 20% and (D) 30% (v/v) of culture ﬁltrate.
Table 2
The percentage of radial growth inhibition of C. gloeosporioides and S. rolfsii by culture
ﬁltrates of B. subtilis SSE4 after 3 days of incubation.
B. subtilis SSE4 culture
ﬁltrate concentration
(%)
% Radial growth inhibition
C. gloeosporioides S. rolfsii
Exponential Stationary Exponential Stationary
10 16.7 88.9 29.4 83.8
20 22.2 94.4 47.1 88.2
30 36.1 100 64.7 92.6
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and ethyl acetate extraction as mentioned above. Thus, 10 ll of
250 lg/ll dried organic extract residue was applied to the ﬁlter pa-
per disk and the zone of growth inhibition around the 7-mm disk
was measured after 24 h of incubation.
2.9. Cell lines
Human Cholangiocarcinoma (HuCCA-1) (Immunology Labora-
tory, Siriraj Hospital, Thailand) and human lung cancer (A549)
(ATCC; CCL-185) were grown in Ham S/F12 medium (Hyclone Lab-
oratories, Logan, UT, USA) containing 2 mM L-glutamine (Sigma,
USA) supplemented with 100 U/ml penicillin–streptomycin (Sig-
ma) and 10% fetal bovine serum (Hyclone Laboratories). Hepato-
carcinoma cells (HepG2) (ATCC; HB-8065), hormone-independent
breast cancer cells (MDA-MB-231) (M. D. Anderson Cancer Center,
USA) and human cervical carcinoma cells (HeLA), (Environmental
Toxicology Laboratory, Chulabhorn Research Institute, Thailand)
were grown in DMEM medium (Hyclone Laboratories) with the
same supplement. Hormone-dependent breast cancer cells (T47D
ATCC HTB-133) were grown in RPMI-1640 medium (Hyclone Lab-
oratories) containing 2 mM L-glutamine and supplemented with
penicillin (100 U/ml), streptomycin (100 U/ml), insulin (0.2 U/ml)
(Sigma), 4.5 g/l glucose and 10% fetal bovine serum.
2.10. Cytotoxic activity testing
Cell lines were plated in 96-well microplates (Costar No. 3599,
USA) at 100 ll/well at a density of 5  103–2  104 cells/well.
Background control well contained the same volume of complete
culture medium. Microplates were incubated for 24 h at 37 C, 5%
CO2 and 95% humidity (Shellab, USA), anticancer drugs at various
concentrations were added and further incubated for 48 h. Cell via-
bility was determined by MTT assay [19,20], which entails staining
with (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (Sigma). The reagent was dissolved in phosphate buffered
saline at 5 mg/ml and ﬁltered. The MTT solution at the ﬁnal con-
centration of 500 lg/ml was added to microplates and incubated
for 2–4 h. Subsequently, 100 ll of dimethyl sulfoxide (DMSO)
(Merck, Germany) was added to dissolve the formed formazan.
The plates were read on a microplate reader (Molecular Devices,
USA), using test and reference wavelengths of 550 and 650 nm,
respectively. IC50 values were determined as the drug concentra-
tion that resulted in a 50% inhibition of cell growth.
2.11. Structure elucidation
All NMR spectra were recorded on a Bruker 600 Avance II spec-
trometer using CD3OD, and H2O + D2O as the solvent. Two-dimen-
sional spectra, DQF-COSY, ed-HSQC, TOCSY, ROESY, NOESY and
HMBC were processed using Bruker XWINNMR software. Infrared
spectra were recorded on a Perkin–Elmer spectrum I spectrometer
and samples were analyzed in the solid phase (UATR) (data in Sup-
plementary data). Mass spectra (HRMS) were obtained on a Bruker
microTOF using atmospheric pressure chemical ionization (APCI)
in positive mode.
3. Results and discussion
3.1. Isolation and identiﬁcation of B. subtilis SSE4
A collection of 143 bacterial strains isolated from shrimp shell
waste were screened for potential antagonistic activity toward
the phytopathogenic fungi, C. gloeosporioides and S. rolfsii, using a
dual culture technique. C. gloeosporioides and S. rolfsii are common
causal agents of anthracnose and collar rot diseases in tropicalfruits and infection by these fungal pathogens results in severe
post-harvest losses [21,22]. One strain, SSE4, was found to express
the highest antagonistic activity against both pathogens. The Gram
positive, rod shaped bacilli was identiﬁed as B. subtilis according to
the sequence of its 16S rRNA gene.
3.2. Radial growth inhibition by extracellular antifungal metabolites
In order to evaluate the antifungal effect of extracellular metab-
olites of B. subtilis SSE4 on the radial growth of C. gloeosporioides
and S. rolfsii. the fungal strains were cultivated on PDA plates con-
taining 10%, 20%, and 30% (v/v) of B. subtilis SSE4 culture ﬁltrate.
When increasing amounts of stationary culture ﬁltrate were added
to the PDA plates, growth of both fungal pathogens were obviously
inhibited (Fig. 1). The fungal growth on the agar plates was mea-
sured daily. The degree of C. gloeosporioides growth inhibition
was proportional to the concentration of culture ﬁltrate in the
media, whereas S. rolfsii was equally inhibited by 10% and 20% cul-
ture ﬁltrate and most inhibited by 30% ﬁltrate concentration. The
ﬁltrates of stationary phase cultures of B. subtilis SSE4 exhibited
higher antifungal activity than those in exponential phase suggest-
ing that the active compound(s) or secondary metabolite(s) may be
preferentially released during the stationary phase of growth
(Table 2).
3.3. Protection of anthracnose disease caused by C. gloeosporioides on
plant leaves
Most Thai orchid exports are of the Dendrobium species. To test
if the active metabolites can protect Dendrobium orchid leaves
from C. gloeosporioides infection, bioassays were performed to
measure the ability B. subtilis SSE4 culture ﬁltrate to suppress fun-
gal infection. Development of anthracnose disease was observed
5 days post-infection in the positive control leaves while treatment
with B. subtilis SSE4 culture ﬁltrate arrested the development of
anthracnose disease lesions to the same extent as the mancozeb
treated leaves (Fig. 2, compare T2, T3, T4 and T5). This is the ﬁrst
experimental demonstration of the use of bioactive compound(s)
to protect orchids from anthracnose disease.
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Fig. 2. The size of lesions on Dendrobium leaves after infection with C. gloeospo-
rioides. T1 neither C. gloeosporioides nor culture ﬁltrates; T2 only C. gloeosporioides;
T3 100 ll of 1 mg/ml of mancozeb and C. gloeosporioides; T4 100 ll of 20% (v/v)
exponential culture ﬁltrate and C. gloeosporioides; T5 100 ll of 20% (v/v) stationary
culture ﬁltrate and C. gloeosporioides.
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Next we examined the antimicrobicidial activity of organic sol-
vent extracts of B. subtilis SSE4 culture ﬁltrates against several bac-
terial strains as well as the yeast Saccharomyces cerevisiae BY 4741
using a disk diffusion inhibition assay. Interestingly, an organic sol-
vent extract of B. subtilis SSE4 culture ﬁltrate was toxic to Gram
negative and Gram positive bacterial strains including human
pathogens such as: Stenotrophomonas maltophilia, which has
emerged as an antimicrobial resistant causative agent of serious
nosocomial infections [23] and AIDS-related disorders [24], Enter-
obacter cloacae, which causes nosocomial bacteremia [25], and
the plant pathogen, Xanthomonas campestris [26] (Table 3). This re-
sult is somewhat unusual since iturins have generally been shown
to display strong antifungal toxicity against a variety of yeast and
fungi but only limited antibacterial activity [27,28]. For example,
bacilopeptins, iturin-group antifungal antibiotics, isolated from B.
subtilis FR-2 were reported to have no antibacterial activity and
only bacilopeptin C exhibited toxicity to several fungi [29]. Also,
neither iturin D nor iturin E have been shown to possess antibacte-
rial activity [4].
3.5. Puriﬁcation of bioactive compounds
The HPLC ﬁngerprint of the residue from ethyl acetate extracts
of extract of B. subtilis SSE4 culture ﬁltrate is shown in Fig. 3. Three
fractions of A (7.20 min), B (9.75 min) and C (16.25–20.75 min),Table 3
Antimicrobial activities of organic solvent extracted compounds.
Microorganisms Diameter (mm)
Acinetobacter calcoaceticus ADP1 20.6
Agrobacterium tumefaciens NTL4 16.0
Enterobacter cloacae 25.6
Escherichia coli TISTR 887 21.6
Klebsiella pneumoniae 11.2
Proteus mirabilis 17.0
Pseudomonas aeruginosa TISTR 1467 12.2
Pseudomonas maltophilia 18.0
Pseudomonas putida 12.0
Rhodobacter capsulatus 15.3
Saccharomyces cerevisiae BY 4741 15.0
Salmonella enteritidis 16.6
Salmonella typhi 14.30
Salmonella typhimurium TISTR 292 22.25
Sinorhizobium meliloti SM1021 17.6
Stenotrophomonas maltophilia K279a 20.6
Xanthomonas campestris 30.0were collected for antibacterial activity assays. The results showed
that fractions A and B did not have any antibacterial activity while
fraction C was found to inhibit bacterial growth (data not shown).
Therefore, we separated this fraction C into four pure fractions (1,
2, 3, and 4) using HPLC and examined these fractions for antibacte-
rial activity. The results indicated that peaks 3 (19.00 min) and 4
(20.75 min) had the highest antibacterial activity (data not shown)
and were therefore collected for further structural analysis (Fig. 3,
Fr. C). Since only peaks 3 and 4 of fraction C have antimicrobial
activity so they were assigned as compounds 1 and 2, respectively.
3.6. Structure elucidation
Both compounds 1 and 2 (Fig. 4) gave a negative reaction with
ninhydrin suggesting that they are cyclic lipopeptides. The micro-
TOF HRMS of compound 1 displayed two major [M+H]+ peaks atm/
z 1043.5497, and 1057.5655, the difference of 14 mass units being
due to the presence of the homologous C14, and C15 b-amino
acids. Thus compound 1 was identiﬁed as a mixture of iturin A2,
C48H74N12O14, and iturin A5, C49H76N12O14.
The microTOF HRMS of compound 2 found m/z 1079.5535
[M+Na]+ of the formula, C49H76N12NaO14, which is a new member
of the lipopeptide family and named as subtulene A. The 1H and 13C
NMR data of subtulene A are nearly identical with that of iturin A.
Twelve carbonyl carbons in the characteristic range dC 177.7–172.8
were observed in the 13C NMR spectrum. Of the twelve carbonyl
carbon signals, eight carbons at dC 175.4 (2C), 174.2, 173.9, 173.1
(2C), 172.9, and 172.8 could be assigned to the carbonyl of a- or
b-amide carbons of the eight amino acid residues. Based on the
molecular formula and the 2D NMR spectra, the four remaining
carbons at dC 177.7 (2C), 175.2, and 174.7 were assigned as the ter-
minal amide carbons of the three asparagine residues and the glu-
tamine residue. Seven a-amino acid protons occurred in the 1H
NMR spectrum in the characteristic range dH 4.00–4.85, while the
a-amino acid carbons showed characteristic peaks in the range
dC 51.6–63.3 in the 13C NMR spectrum. Seven NHa protons, one
NHb proton, eight NHamide protons, and two hydroxy protons oc-
curred at low ﬁled in the characteristic range dH 6.81–9.15 in the
1H NMR spectrum corresponding to the assignment (see Table 2
in Supplementary data).
In the 1H NMR spectrum, two pairs of doublets at dH 7.01 (2H,
J = 8.3 Hz) and dH 6.64 (2H, J = 8.3 Hz) could be attributed to the
protons corresponding to the aromatic carbons of the tyrosine res-
idue as shown in the 13C NMR spectra at dC 157.4 (C), 131.2 (2CH),
129.0 (C), and 116.5 (2CH), respectively. The carbon signals at dC
62.9 (methylene, C-33) and dC 57.4 (methine, C-32) are very char-
acteristic of a serine residue and showed a strong correlation in the
COSY and TOCSY spectra. The proline residue protons and carbons
were assigned based on the TOCSY and HSQC spectra. The set of
proline protons showed the a-amino proton at dH 4.23 (1H,
J = 7.3 Hz) and three methylene protons as multiplet at dH 1.95
(2H), 2.14, 2.17, 3.80, and 3.95, which corresponding to signals in
the 13C NMR spectrum at dC 63.3 (C-23), 30.5 (C-24), 26.2 (C-25),
and 49.0 (C-26), respectively.
The carbon signals at dC 43.7 and 48.1 are very characteristic of
a b-amino acid and could be assigned to the a-CH2 (C-36) and b-CH
(C-35, adjacent to NH) of the long chain b-amino acid. The doublet
signal at dH 0.85 (6H, 2  CH3) in the 1H NMR spectrum and at dC
23.0 in the 13C NMR spectrum was assigned to the isopropyl group
of the long chain. The oleﬁnic protons and carbons at dH 5.23 (2H)
in the 1H NMR spectrum and at dC 129.1 and 130.9 in the 13C NMR
spectrum suggested that the long chain b-amino acid contained a
1,2-disubstituted double bond. Based on the HMBC correlation,
the position of the double bond was assigned at C42–C43 position
[11]. The presence of an unsaturated double bond is unique among
the members of the iturin family. The absolute stereochemistry
Fig. 3. Puriﬁcation of bioactive compounds using HPLC. The HPLC ﬁngerprint of the residue from an ethyl acetate extract of the culture ﬁltrate of B. subtilis SSE4.
1 Iturin A: R = H, C42-C43
2 Subtulene A: R = CH3, C42=C43
N
H
HN
H
NN
H
N
H
H
N
HN
N
O
O O
O
O
O
O
O
H
HO
O
H2N
H2N
O
O
H2N
H2N
O
OH
R
48
43
42
35
371
20
23
5
14
18
28
32
Fig. 4. Structure of iturin A (1) and subtulene A (2).
N
N
NN
N
N
N
N
O
O
O
O
O
O
O
O
H
O
H2N
O
H2N
O
H2N
H2N
O
OH
H
48
43
42
35
371
21
23
515
18
28
32
TOCSY
HMBC (H C)
H
H
H H
H
H
H
H
H
H
HH
H
H
H
H
H
H
38
46
ROESY (H H)
H
25
10
H
OH
H
H
H
H H
H
HH
H
Fig. 5. Selected TOCSY, HMBC and NOESY spectrum of subtulene A (2).
N. Thasana et al. / FEBS Letters 584 (2010) 3209–3214 3213was determined to be in the R-conﬁguration at the b-carbon (C35)
same as the previous reports [5,6].
The sequence of the eight amino acid residues was determined
by analyzing the ROESY and HMBC spectrum as shown in Fig. 5. Six
NHa protons and one NHb proton of the eight amino acid residues
showed sequently cross correlations altogether with the seven CHa
protons and one CHb proton in ROESY spectrum. Seven CHa pro-
tons and one CHb proton correlated to the carbonyl of a- and b-
amide carbons of the eight amino acid residues in HMBC spectrum.
The results of TOCSY, ROESY and HMBC correlations concluded thesequence of eight amino acids of subtulene A as L-Asn-1, D-Tyr-2, D-
Asn-3, L-Gln-4, L-Pro-5, D-Asn-6, L-Asn-7, and b-amino acid-8,
respectively.
3.7. Cytotoxic activities of subtulene A
In order to test if our new compound, subtulene A, posses any
antitumor activity, the IC50 values for subtulene A were deter-
mined in ﬁve cancer cell lines with the anticancer drug doxorubi-
cin serving as a positive control. Subtulene A did not exhibit
signiﬁcant cytotoxic effects toward the cell lines tested (data not
shown). To date, there is only one report of iturins having antitu-
mor activity. Mixirins A, B and C, which were isolated from a mar-
ine Bacillus sp., were reported to inhibit the human colon tumor
cell line, HCT-116 [30]. However, no experimental details were
given.
4. Conclusion
We isolated B. subtilis SSE4 that produces the extracellular anti-
microbial compounds iturin A (1) and a new member of the lipo-
peptide family, subtulene A (2). Subtulene A has a unique long
iturinic acid side chain of 3-amino-13-methyltetradec-8-enoic
acid. This is the ﬁrst report of an antibiotic belonging to the iturin
family in which the lipid side chain contains a double bond.
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